Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

Comparison of 18F-FDGSUV, QSM and T2*values between Parkinson’s disease and healthy controls from a single exam

Yan Bai, Yaping Wu, Jianmin Yuan, Yang Yang, Yongquan Ye, Xiaochen Li, Wei Wei, Yan Yang, Menghuan Zhang and Meiyun Wang
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1080;
Yan Bai
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaping Wu
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianmin Yuan
2Central Research Institute, UIH Group, Shanghai, China Shanghai China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Yang
3Central Research Institute, UIH Group, Beijing, China Beijing China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongquan Ye
4UIH America, Inc., Houston, TX, United States Houston, TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaochen Li
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Wei
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Yang
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Menghuan Zhang
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meiyun Wang
1Henan Provincial People’s Hospital & the People’s Hospital of Zhengzhou University Zhengzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1080

Introduction: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders1,2 mostly occurred in elderly people. Positron emission tomography (PET) and magnetic resonance (MR) imaging are the two techniques that can detect brain function. While previous research normally use separate scans and MRI involves multiple sequences, the exam is normally time consuming. In an integrated PET/MR scanner together with advanced MRI techniques, the PET and multi-contrast MR images could be obtained simultaneously using one sequence, which is helpful to investigate the metabolism and neural activity of PD, without further image registration. In this study, we compared the standardized uptake value (SUV), quantitative susceptibility mapping (QSM) and T2* values between PD and healthy controls (HC) from a single sequence PET/MR scan.

Methods: Eight PD patients and eight HC were participated in this study. Signed informed consent was obtained from each participant prior to study enrollment. The institutional ethics committee approved this study and all participants gave informed written consent. The data were collected on a 3.0 T PET/MR system (uPMR790, UIH, Shanghai, China) with 32 channel head coil. 18F-FDG PET and MULTIPLEX sequence were performed to generate SUV, QSM and T2* images, together with anatomic T1w simultaneously. The substantia nigra was chosen as the region of interest (ROI) and the ROI of each participant was drawn on the workstation. Mean SUV, QSM and T2* values of each ROI were obtained and t-tests were performed on the data. Moreover, the sex and age covariates were regressed out when doing t-tests.

Results: The example of 18F-FDG PET, QSM and T2* images from a PD patient and HC were shown in Fig. 1 . As shown in Table 1, the SUV and T2* values of PD were significantly lower than HC (p < 0.05) and the QSM values of PD were significantly higher than HC (p < 0.05). Conclusion: The 18F-FDG SUV, QSM and T2* values showed significant difference between PD patients and HC, which suggested that these three parameters probably be biomarkers of PD. Integrated PET/MR with the advanced MR sequence allows to obtain these quantitative information from a single exam, which can be a useful technique to investigate the physiological and neural mechanism of PD.References:[1] Saeed U, Compagnone J, Aviv R I, et al. Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts[J]. Translational neurodegeneration, 2017, 6(1): 8.[2] He R, Yan X, Guo J, et al. Recent advances in biomarkers for Parkinson’s disease[J]. Frontiers in aging neuroscience, 2018, 10: 305.

View this table:
  • View inline
  • View popup

Table 1. Comparing SUV, QSM and T2* between PD and HC

Fig. 1 A patient with Parkinson’s disease (A-C). A T2* map shows that signal intensities decrease in the substantia nigras; B QSM map shows that signal intensities increase in the substantia nigras; C 18F-FDG PET image shows that SUV decreases in the substantia nigras. A heanthy control (D-F). A T2* map; B QSM map; C 18F-FDG PET image.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of 18F-FDGSUV, QSM and T2*values between Parkinson’s disease and healthy controls from a single exam
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparison of 18F-FDGSUV, QSM and T2*values between Parkinson’s disease and healthy controls from a single exam
Yan Bai, Yaping Wu, Jianmin Yuan, Yang Yang, Yongquan Ye, Xiaochen Li, Wei Wei, Yan Yang, Menghuan Zhang, Meiyun Wang
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1080;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of 18F-FDGSUV, QSM and T2*values between Parkinson’s disease and healthy controls from a single exam
Yan Bai, Yaping Wu, Jianmin Yuan, Yang Yang, Yongquan Ye, Xiaochen Li, Wei Wei, Yan Yang, Menghuan Zhang, Meiyun Wang
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1080;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • A clinical study of baseline PET/CT parameters in the prediction of refractory/ relapsed diffuse large B cell lymphoma of advanced stage patients
  • A head-to-head comparison of the Lugano Classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma
Show more Poster - PhysicianPharm

Neurology and Psychiatry

  • Sex modifies the APOE e4 dose dependent effect on brain region-specific tau deposition measured by 18F-flortaucipir PET in individuals with cognitive impairment
  • Semiquantitative Approach to Amyloid PET Interpretation in Clinical Practice
  • Monkey, rat, and first in human evaluation of [18F]PF-06445974, a PET radioligand that preferentially labels phosphodiesterase 4B
Show more Neurology and Psychiatry

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire